Developing a green synthesis process for a growth promoter drug for animals

Learn how Syngene developed a green synthesis process for a growth promoter drug for an animal health company that reduced the cE factor and PMI value by 80% while achieving high yield and cost-efficiency.

Author

Latest Blogs

Why CDMO Outsourcing is Moving Earlier in Biologics Development

Infographic showing the shift from traditional pharma outsourcing based on cost and capacity to a new-age CRDMO model focused on scientific depth, speed, supply-chain resilience, integration, and development flexibility.

The New-Age CRDMO: Rethinking Drug Development Partnerships

Flow Chemistry Approaches for Poorly Soluble Pharmaceutical Intermediates

Advanced Strategies for Handling Unstable Intermediates with Flow Chemistry

Electrochemical cell design: Turning electron transfer into a practical synthetic tool

Semi-targeted integration in cell line development supports stable clone selection and more predictable biologics development.

From Faster CLD to Smarter CMC Decisions: How Semi-Targeted Integration Changes the Biologics Game